These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 23585006)
1. [Comparison of skin sympathetic reaction in patients with generalized anxiety disorder and with major depression disorder]. Jiang H; Wang L; Wang X; Feng R; Zhang Y; Tu L; Chen W Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 Mar; 42(2):192-6. PubMed ID: 23585006 [TBL] [Abstract][Full Text] [Related]
2. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. Griebel G; Beeské S; Stahl SM J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246 [TBL] [Abstract][Full Text] [Related]
3. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. Demyttenaere K; Andersen HF; Reines EH Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937 [TBL] [Abstract][Full Text] [Related]
4. Psychophysiological correlates of generalized anxiety disorder with or without comorbid depression. Hofmann SG; Schulz SM; Heering S; Muench F; Bufka LF Int J Psychophysiol; 2010 Oct; 78(1):35-41. PubMed ID: 20093149 [TBL] [Abstract][Full Text] [Related]
5. The differences of event-related potential components in patients with comorbid depression and anxiety, depression, or anxiety alone. Zhou X; Lin Z; Yang W; Xiang M; Zhou B; Zou Z J Affect Disord; 2023 Nov; 340():516-522. PubMed ID: 37572703 [TBL] [Abstract][Full Text] [Related]
6. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. Sheehan DV; Harnett-Sheehan K; Spann ME; Thompson HF; Prakash A Int Clin Psychopharmacol; 2011 Mar; 26(2):75-83. PubMed ID: 21102344 [TBL] [Abstract][Full Text] [Related]
7. Disorder-specific impaired neurocognitive function in major depression and generalized anxiety disorder. Luo W; Luo L; Wang Q; Li Y; Zhang Y; Hu Y; Yu Y; Yu S; Lu F; Chen J; Liu L; Du N; Langley C; Sahakian BJ; He Z; Li T J Affect Disord; 2022 Dec; 318():123-129. PubMed ID: 36057290 [TBL] [Abstract][Full Text] [Related]
8. The network structure of major depressive disorder, generalized anxiety disorder and somatic symptomatology. Bekhuis E; Schoevers RA; van Borkulo CD; Rosmalen JG; Boschloo L Psychol Med; 2016 Oct; 46(14):2989-2998. PubMed ID: 27523095 [TBL] [Abstract][Full Text] [Related]
9. Putative Antidepressant Effect of Chamomile ( Amsterdam JD; Li QS; Xie SX; Mao JJ J Altern Complement Med; 2020 Sep; 26(9):813-819. PubMed ID: 31808709 [No Abstract] [Full Text] [Related]
10. Major depressive disorder and generalized anxiety disorder show different autonomic dysregulations revealed by heart-rate variability analysis in first-onset drug-naïve patients without comorbidity. Shinba T Psychiatry Clin Neurosci; 2017 Feb; 71(2):135-145. PubMed ID: 27987241 [TBL] [Abstract][Full Text] [Related]
11. Predictors of persistence of comorbid generalized anxiety disorder among veterans with major depressive disorder. Mittal D; Fortney JC; Pyne JM; Wetherell JL J Clin Psychiatry; 2011 Nov; 72(11):1445-51. PubMed ID: 21208594 [TBL] [Abstract][Full Text] [Related]
12. Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications. Casacalenda N; Boulenger JP Can J Psychiatry; 1998 Sep; 43(7):722-30. PubMed ID: 9773222 [TBL] [Abstract][Full Text] [Related]
13. [A study of sympathetic skin response to the damage of autonomic nerves function in patients with chronic N-hexane poisoning]. Situ J; Wu J; Wang JL; Zhu DX; Zhang JJ; Liu WW; Qin ZH Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2012 May; 30(5):339-42. PubMed ID: 22804985 [TBL] [Abstract][Full Text] [Related]
14. Hypoesthesia in generalised anxiety disorder and major depression disorder. García-Blanco A; González-Valls P; Iranzo-Tatay C; Rojo-Moreno L; Sierra P; Livianos L Int J Psychiatry Clin Pract; 2018 Nov; 22(4):310-313. PubMed ID: 29320917 [No Abstract] [Full Text] [Related]
15. Association between olfactory function and inhibition of emotional competing distractors in major depressive disorder. Wang F; Jin J; Wang J; He R; Li K; Hu X; Li Y; Zhu Y Sci Rep; 2020 Apr; 10(1):6322. PubMed ID: 32286450 [TBL] [Abstract][Full Text] [Related]
16. Disorder-specific cognitive profiles in major depressive disorder and generalized anxiety disorder. Hendriks SM; Licht CM; Spijker J; Beekman AT; Hardeveld F; de Graaf R; Penninx BW BMC Psychiatry; 2014 Apr; 14():96. PubMed ID: 24690413 [TBL] [Abstract][Full Text] [Related]
17. Sympathetic Skin Response in Amyotrophic Lateral Sclerosis. Hu F; Jin J; Qu Q; Dang J J Clin Neurophysiol; 2016 Feb; 33(1):60-5. PubMed ID: 26844971 [TBL] [Abstract][Full Text] [Related]
18. Comparison of automatical thoughts among generalized anxiety disorder, major depressive disorder and generalized social phobia patients. Gül AI; Simsek G; Karaaslan Ö; Inanir S Eur Rev Med Pharmacol Sci; 2015 Aug; 19(15):2916-21. PubMed ID: 26241548 [TBL] [Abstract][Full Text] [Related]
19. Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorder. Zhou Y; Cao Z; Yang M; Xi X; Guo Y; Fang M; Cheng L; Du Y Sci Rep; 2017 Jan; 7():40511. PubMed ID: 28098176 [TBL] [Abstract][Full Text] [Related]
20. Neurobiological signatures of anxiety and depression in resting-state functional magnetic resonance imaging. Oathes DJ; Patenaude B; Schatzberg AF; Etkin A Biol Psychiatry; 2015 Feb; 77(4):385-93. PubMed ID: 25444162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]